Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

y lead to the first approval for phenoxodiol," Mr. Naughton said.

In a prior Phase II clinical trial, phenoxodiol was tested in combination with either cisplatin or paclitaxel. Patients with late stage ovarian cancer that had become refractory to platinum or paclitaxel therapy, following multiple courses of chemotherapy, were treated with phenoxodiol and cisplatin or phenoxodiol and paclitaxel, respectively. Of 21 patients in the cisplatin arm there were six partial responders, nine patients with stabilised disease and six patients who had disease progression; of 19 in the paclitaxel arm, there was one complete responder, two partial responders, eleven with stabilised disease and five patients who had disease progression. There were few side effects associated with phenoxodiol, but, as with any investigational drug, there is a possibility of unexpected side effects.

Professor Ignace Vergote, the Principal Investigator at the Leuven site was Chairman of the EORTC Gynaecologic Cancer Group from 1997 to 2003, and still chairs the Protocol Committee of that group. He is currently the President of the International Cancer Society and Immediate Past-President of the European Society of Gynaecologic Oncology.

Women who are interested in participating in the OVATURE trial, or who simply wish to learn more about this study, should visit http://www.OVATUREtrial.com or visit http://clinicaltrials.gov/ (type OVATURE in the search box).

About phenoxodiol: Phenoxodiol is being developed as a therapy for late- stage, chemo-resistant prostate, ovarian and cervical cancers. Phenoxodiol is an investigational drug and, as such, is not commercially available. It is a novel-acting drug that inhibits key pro-survival signalling pathways operating via sphingosine-1-phosphate and Akt. Inhibition of these pathways leads to prevention of phosphorylation of ke
'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... YORK, Oct. 26, 2011 One week after a ... most serious of skin cancers, which causes 8,000 U.S. ... Skin Association (ASA), a collaboration of patients, families, advocates, ... scientists who have made groundbreaking discoveries and unique contributions ...
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that its ... $0.08 per share, payable on December 13, 2011 ... Perrigo Company is a leading global ... and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional ...
Cached Medicine Technology:American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 2American Skin Association Honors Leading Physicians and Scientists; Journalist Deborah Norville 3
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
(Date:7/9/2014)... world have been linked to an emerging fungal ... National Institute for Mathematical and Biological Synthesis (NIMBioS) ... , In a series of mathematical models, ... of internal organs in frogs, could cause extinction ... are exposed to the virus every few years, ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... , , , ... , , , , ... from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University of Southampton researchers, with assistance ...
(Date:7/8/2014)... similar longevity and cardiovascular health as other healthy mature ... American Journal of Transplantation . The findings may ... the transplant professionals caring for them. , Over the ... 55 years and older has become more common. Given ... disease, the removal of a kidney could make older ...
Breaking Medicine News(10 mins):Health News:Study cracks how the brain processes emotions 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:Study finds kidney donation safe for healthy older adults 2
... cells, stem cells derived from human placenta left over ... when they interacted with one kind of melatonin receptor, ... cells were transplanted into laboratory test tube and animal ... perform similarly when interacting with melatonin receptor MT2. ...
... 1, 2011) Positron emission tomography (PET) can ... kinase inhibitor vandetanib, helping to define the therapy ... according to research published in the February issue ... Currently being tested in clinical trials, vandetanib inhibits ...
... Society for Therapeutic Radiology and Oncology (ESTRO), the European ... for Medical Oncology (ESMO) in collaboration with other European ... on the 3rd International Conference on innovative approaches In ... on multidisciplinarity and innovation, this meeting will specifically cover ...
... and ultrasound can mean more targeted breast biopsies for ... and possibly saving those patients from undergoing a second ... Patients with early breast cancer undergo a sentinel lymph ... said Dr. Ali Sever, lead author of the study. ...
... -- Among injection drug users, new cases of HIV infection ... number of new infections from the hepatitis C virus have ... The findings suggest that efforts -- such as needle exchange ... of infectious diseases have been successful against HIV but more ...
... professionals have talked about youth pitching injuries and the stress ... new, 10-year study published in the February issue of the ... participants who pitched more than 100 innings in a year ... study proved a direct link between innings pitched in youth ...
Cached Medicine News:Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:PET scans may allow early prediction of response to targeted therapy of thyroid cancer 2Health News:3rd international conference on innovative approaches in head and neck oncology 2Health News:Microbubble ultrasound and breast biopsies 2Health News:Infectious Disease Experts Call for More Focus on Hepatitis C 2Health News:New 10-year study confirms too many pitches strike out youth athletes early 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: